B lymphocyte activating factor (BAFF), a member of the tumour necrosis factor family, is essential for B cell activation, differentiation and survival.
14 Circulating BAFF levels have been found to be elevated in patients with GD, 15 and those with other autoimmune diseases. 16 A recent case-control association study highlighted an intronic BAFF single nucleotide polymorphism (SNP), rs2893321, as a susceptibility variant for the development of GD in the Taiwanese population. 17 In addition, the T allele of a BAFF promoter SNP (rs9514828) has been associated with susceptibility to systemic lupus erythematosus (SLE) in Egyptians, 18 and immune thrombocytopenic purpura (ITP) in Chinese and German cohorts. 19, 20 These SNPs are not in linkage disequilibrium (LD). It is essential to study autoimmune disease susceptibility alleles in several populations encompassing a wide variety of ethnic backgrounds to confidently identify the aetiologically important variants that may then cast light on functional mechanisms.
In this study, we explore the association of two BAFF SNPs in a cohort of UK patients with GD.
| PATIENTS AND ME THODS

| Patients
Each subject with GD was diagnosed by the following criteria: (a)
fully suppressed serum TSH with serum free thyroxine and/or free triiodothyronine above the reference range, and (b) the existence of detectable TSH receptor antibody (TRAb; ≥1.8 mU/L; Brahms Kryptor).
Informed, written consent was obtained from all participants.
The Whickham study from which the healthy control samples 
| SNP genotyping
In this study, two haplotype blocks of the BAFF gene were explored, using a tag SNP approach. A commercially available TaqMan assay for rs2893321, which was previously associated with GD in a Taiwanese population, 17 was not available and therefore the intronic SNP, rs4000607, was selected for analysis. This SNP is in complete LD with rs2893321 (r 2 = 1.0; D′ = 1.0). 21 A second SNP rs9514828, in the BAFF promoter region, was also selected for analysis. This SNP has previously been associated with SLE and ITP. PLINK was used to calculate LD between rs9514828 and rs2893321 in the WTCCC2 dataset and they were found to be independent (r 2 = 0.001; D′ = 0.046).
22
Genomic DNA extracted from venous blood was genotyped using TaqMan SNP genotyping assays as per the manufacturer's instructions (assay C_29641742_10 for rs9514828; assay C_27350172_10 for rs4000607) using the 7900 HT Fast Real-Time PCR system (Applied Biosystems). Twenty per cent of the samples were genotyped in duplicate to ensure assay fidelity.
| Statistical analysis
Statistical power for this study was calculated, 23 with the assumption of a minor allele frequency (MAF) of 0.22 in the 5159 Wellcome
Trust case-control consortium (WTCCC2) cohort and a type 1 error rate (α) of 0.05, giving an estimate of 87% power to detect an odds ratio of 1.3 with 400 GD cases.
Statistical association analysis was performed using SHEsis. 24 All the control sample genotypes were in Hardy-Weinberg equilibrium (HWE; P > 0.4). There were no significant differences between allele frequencies in the local control samples compared to the publicly available WTCCC2 controls (P = 0.58) ( Table 1) .
| RE SULTS
There was a significant difference in the frequency of the AA genotype at rs4000607 between the GD cohort (46/444; 10%) and both local (27/447; 6%: P = 0.045) and WTCCC2 control groups (254/5157; 5%: P = 4.56 × 10 −6 ) ( Table 2 ).
In contrast, there was no significant difference in either genotype or allele frequencies at rs9514828 between the GD and either control group (Table 3) .
| D ISCUSS I ON
A complex interaction between susceptibility alleles, immunological, environmental and stochastic factors predispose to the breakdown of immune tolerance and subsequent development of GD. 25 The vast majority of GD susceptibility variants are yet to be discovered.
Our study has demonstrated a significant association of a BAFF variant (rs4000607) with GD in a UK cohort, which confirms previous findings in a Taiwanese population. 17 The finding of an excess TA B L E 3 Genotype and allele frequencies at rs9514828 in GD and healthy controls genes, BAFF has an important role in immune system function. The crucial role that BAFF has in controlling B cell activation, differentiation and survival make it a plausible biological candidate for GD which is a B lymphocyte mediated condition. BAFF is a type II membrane protein that exists either in membrane-expressed or soluble cytokine form, both of which are capable of eliciting B cell activation. 27 Elevated serum BAFF levels have been found in patients with several autoimmune diseases, including GD. 15, 16 The expression of BAFF and its receptor (BAFF-R) have also been demonstrated to be elevated in infiltrating lymphocytes in GD thyroid tissue. 28 The rs4000607 SNP that was found to be associated with GD in our study is in complete LD (r 2 = 1.0; D′ = 1.0) with rs12583006, 22 which has been associated with susceptibility to both SLE and primary
Sjögren's syndrome. 32 Considering the close proximity of these SNPs to 
| CON CLUS ION
We have demonstrated a significant association of the BAFF SNP rs4000607 with GD in a UK cohort for the first time. Our findings indicate a potential role for BAFF as a contributor to autoimmune GD susceptibility, supporting it as a potential candidate gene for the development of targeted immunotherapy. Further work to elucidate the role of BAFF in the pathogenesis of GD is now warranted.
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